The USFDA approves Zydus' generic medication for postherpetic neuralgia
 |
| The USFDA approves Zydus' generic medication for postherpetic neuralgia |
According to the statement, the pharmaceutical business is the first to have its generic gabapentin pills (300 mg and 600 mg) approved officially. The pharmaceutical corporation said that the medicine will be on sale right away in the United States.
IQVIA data indicates that the product sold for US$85 million annually in the US.
On Thursday, Zydus Lifesciences said that the US health agency has given the company permission to commercialize a generic medication for the treatment of postherpetic neuralgia. Zydus Lifesciences announced in a regulatory filing that the US Food and Drug Administration (USFDA) has given the business final clearance to produce and sell gabapentin tablets in strengths of 300 mg and 600 mg, respectively.
According to the statement, the pharmaceutical business is the first to have its generic gabapentin pills (300 mg and 600 mg) approved officially. The pharmaceutical corporation said that the medicine will be on sale right away in the United States. IQVIA data indicates that the product sold for US$85 million annually in the US. On the BSE, Zydus shares were down 2.27 percent at Rs 735.30.
Reviewed by Gourav kumar singh
on
January 28, 2024
Rating:
No comments:
Post a Comment